(Q47597667)

4 February 2018

title

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. (English)

1 reference

4 February 2018

1 reference

Evelyne Jacqz-Aigrain

5

1 reference

4 February 2018

Pierre Laurent-Puig

6

1 reference

4 February 2018

Mikko Niemi

8

1 reference

4 February 2018

Ann K Daly

17

1 reference

4 February 2018

Mia Wadelius

object named as

Mia Wadelius

16

0 references

Hiltrud Brauch

4

object named as

Hiltrud Brauch

1 reference

4 February 2018

Laurent Becquemont

1

1 reference

4 February 2018

Ana Alfirevic

2

1 reference

4 February 2018

Ursula Amstutz

3

1 reference

4 February 2018

Miguel A Molina

7

1 reference

4 February 2018

Matthias Schwab

9

1 reference

4 February 2018

Andrew A Somogyi

10

1 reference

4 February 2018

Eric Thervet

11

1 reference

4 February 2018

Anke-Hilse Maitland-van der Zee

12

1 reference

4 February 2018

André Bp van Kuilenburg

13

1 reference

4 February 2018

Ron Hn van Schaik

14

1 reference

4 February 2018

Céline Verstuyft

15

1 reference

4 February 2018

publication date

1 January 2011

1 reference

4 February 2018

published in

Pharmacogenomics

1 reference

4 February 2018

volume

12

1 reference

4 February 2018

page(s)

113-124

1 reference

4 February 2018

issue

1

1 reference

4 February 2018

Screening for epidermal growth factor receptor mutations in lung cancer

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Genetics: Predictive value of KRAS mutations in chemoresistant CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Transporter pharmacogenetics and statin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.147

21 January 2018

Identifiers

DOI

10.2217/PGS.10.147

1 reference

4 February 2018

PubMed ID

21174626

1 reference

4 February 2018